| scholarly article | Q13442814 |
| P2093 | author name string | Massimo Porena | |
| Michele Del Zingaro | |||
| Ettore Mearini | |||
| Antonella Giannantoni | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 705-711 | |
| P577 | publication date | 2008-09-02 | |
| P1433 | published in | European Urology | Q15763991 |
| P1476 | title | Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results | |
| P478 | volume | 55 |
| Q45842565 | A retrospective study on female urological surgeries over the 10 years following spinal cord lesion. |
| Q38181065 | Advances in the management of neurogenic detrusor overactivity in multiple sclerosis |
| Q44539406 | An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity |
| Q91669524 | Ancillary benefits of bladder chemodenervation for SCI neurogenic bladder |
| Q37248174 | Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity |
| Q38271905 | Autonomic consequences of spinal cord injury |
| Q37801072 | Botulinum Toxin Therapy for Neurogenic Detrusor Overactivity |
| Q85205665 | Botulinum Toxin-A Injections Into Neurogenic Overactive Bladder—To Include or Exclude the Trigone? A Prospective, Randomized, Controlled Trial |
| Q36313192 | Botulinum toxin in neurogenic detrusor overactivity |
| Q37581341 | Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity |
| Q53081459 | Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan. |
| Q48500221 | Catheter-associated urinary tract infections in persons with neurogenic bladders |
| Q37049870 | Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder |
| Q36395728 | Clinical uses of botulinum neurotoxins: current indications, limitations and future developments |
| Q48773589 | Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity |
| Q35237161 | Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective |
| Q38564108 | Current and potential urological applications of botulinum toxin A. |
| Q84974689 | Diagnosis and treatment of overactive bladder, neurourology, urogynaecology and urinary stress incontinence: latest publications from 2009 and 2010 |
| Q44739294 | Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity |
| Q52679112 | Effects of Dietary Vitamin E Supplementation in Bladder Function and Spasticity during Spinal Cord Injury. |
| Q38115204 | Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review |
| Q37812561 | Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity |
| Q26765052 | How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage? |
| Q36855832 | Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment |
| Q47994885 | Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment? |
| Q47379554 | Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study |
| Q47221995 | Intravesical Electromotive Botulinum Toxin Type "A" Administration for Management of Urinary Incontinence Secondary to Neuropathic Detrusor Overactivity in Children: Long-Term Follow-up |
| Q43181602 | Intravesical injections of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods |
| Q39459240 | Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity-A systematic review and meta-analysis |
| Q58421371 | Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB) |
| Q38525503 | Lower urinary tract dysfunction in the neurological patient: clinical assessment and management |
| Q48089934 | Macroplastique and Botox are superior to Macroplastique alone in the management of neurogenic vesicoureteric reflux in spinal cord injury population with presumed healthy bladders. |
| Q28087196 | Neurogenic bladder in spinal cord injury patients |
| Q97570183 | Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA |
| Q92583570 | Nocturia in Parkinson's Disease: Why Does It Occur and How to Manage? |
| Q28087509 | Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection |
| Q38233836 | OnabotulinumtoxinA (Botox(®)): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury |
| Q26826756 | OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review |
| Q48303526 | OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity |
| Q37834654 | Pharmacotherapy for overactive bladder: minimally invasive treatment -- botulinum toxins |
| Q37817727 | Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity |
| Q62626416 | Repeated Injections of Botulinum Toxin-A for Idiopathic Detrusor Overactivity |
| Q46963074 | Side effects of intradetrusor botulinum toxin injections on ejaculation and fertility in men with spinal cord injury: preliminary findings |
| Q37801067 | Spinal cord/brain injury and the neurogenic bladder. |
| Q38239522 | The evaluation and management of refractory neurogenic overactive bladder |
| Q48279466 | The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients |
| Q36830702 | The use of botulinum toxin for the treatment of overactive bladder syndrome |
| Q52683629 | The use of urodynamic studies for the followup of neurogenic bladders treated with onabotulinumtoxinA. |
| Q48389748 | Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity |
| Q39019524 | Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls |
| Q26851170 | Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review |
| Q48238470 | Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment |
Search more.